Efficacy of Daily Ivermectin Treatment in a Dog with Amitraz-Resistant, Generalized Demodicosis

Abstract— A six-year-old intact male English setter dog with chronic, juvenile-onset, generalized demodicosis, resistant to amitraz, was treated with ivermectin given orally 600 mcg/kg once daily, for more than 7 months. The dog was clinically normal after 4 months and skin scrapings were negative for Demodex canis mites after 7 months of treatment. Résumé— Un chien male de six ans de race Setter Anglais souffrant d'une démodécie généralisée chronique depuis l'âge de trois mois et résistante à l'Amitraz, fut trait à l'aide d'ivermectine par voie orale, à la dose quotidienne de 600 mcg/kg pendant plus de sept mois. Un rémission des signes cliniques fut obtenue après 4 mois et les raclages cutanés se sont révélés négatifs pour Demodex canis après 7 mois de thérapie. Zusammenfassung— Ein 6 Jahre alter, nicht kastrierter Englisch-Setterrüde wurde mehr als 7 Monate mit Ivermectin per os, 600 mcg/kg einmal täglich, behandelt, da er unter einer chronischen, in jugendlichem Alter ausgebrochenen generalisierten Demodikose litt, die auf Amitraz nicht ansprach. Das Tier war nach 4 Monaten klinísch gesund, 7 Monate nach der Behandlung fielen Hautgeschabsel auf Demodex-canis-Milben negativ ans. Schlüsselwörter: Hund; Haut; Demodilose; Ivermectin. Resumen Un perro mecho enteros de seis años de la raza setter inglés presentando una demodicosis generalizada crónica de aparición juvenil, y que presentaba resistencia al almitraz, fue tratada con avermectina administrada oralmente a una dosis de 600 mcg/kg, una vez al día, y por un periodo de más de 7 meses. Después de 4 meses, la aparición clinica del perro era normal y los raspados cutaneos no demonstraron la presencia de Demodex canis despues de 7 meses de tratamiento.     

Ivermectin effects on motor coordination and contractions of isolated rat diaphragm

Ivermectin, the antiparasitic drug from the macrocyclic lactones class raises attention due to its high efficiency against nematodes and arthropods and very specific toxic and side effects that it may produce in host. Dominant clinical symptoms of adverse effects and toxicity of ivermectin in animals are tremor, ataxia, CNS depression and coma which often results in mortality. In our study increasing intravenous doses of ivermectin, (6 or more times higher than therapeutic dose: 1.25, 2.5, 3.75, 5.0, 6.25 and 7.5 mg/kg), caused dose-dependent disturbance of motor coordination in treated rats. The median effective dose (ED50) that was able to impair the rota-rod performance in rats treated 3 min before testing was 2.52 mg/kg. This effect weakens over time, while in the rats treated 60 min before the rota-rod test, ED50 of ivermectin was 4.21 mg/kg. Whereas, all tested doses of ivermectin did not cause any other clinical symptoms of toxicity. Ivermectin has no effect on the contractions of isolated diaphragm caused by the EFS, which effectively blocked mecamylamine (100 μM) and pancuronium (1 and 2 μM). Effect on motor coordination is the first detectable clinical symptom of ivermectin toxicity and apparently is a result of its central effects.     

Efficacy of thiabendazole, mebendazole, levamisole and ivermectin against gullet worm, Gongylonema pulchrum: in vitro and in vivo studies

In vitro and in vivo studies were conducted to evaluate the effects of thiabendazole, mebendazole, levamisole and ivermectin against Gongylonema pulchrum. For in vitro assays, third-stage larvae (L3) incubated with the drugs were administered orally to mice and the ability of larvae to invade the gastric mucosa of the animals was examined. After incubation, only those larvae treated with high concentrations of levamisole (1 and 10 microg/ml) were tightly coiled with intestines exhibiting morphological abnormalities. Good dose-response data for the drugs tested was observed at the time of worm recovery from mice, with no worms recovered at the two highest concentrations of levamisole. In vivo efficacy of the drugs against adult worms was evaluated in six groups of three rabbits, each of which was infected with 30 L3 of G. pulchrum and treated with thiabendazole at 100 mg/kg for 3 days, mebendazole at 70 mg/kg for 3 days, levamisole as a single dose of 8 mg/kg, and subcutaneously injected ivermectin as a single dose of 0.2 mg/kg or vehicles of the drugs (control) at 4 months post-infection. Necropsy 14 days after treatment revealed that levamisole, mebendazole and ivermectin reduced worm burdens by 63.2%, 22.8% and 25.8%, respectively, with no reductions in worms observed with thiabendazole. The surviving worms were principally found in the esophagus with the remainder distributed among the buccal mucosa, the tongue, and/or pharyngeal mucosa in all groups. A number of morphologically abnormal eggs were observed within the uterus and ovijector in female worms recovered from the thiabendazole-treated group. These findings suggest that levamisole exhibits in vivo efficacy against G. pulchrum infection and that the larval invasion tests using mice could be used to screen for anthelmintic susceptibility of nematodes.     

喷蒸真空热压对水溶性PF胶在杨木大片刨花中的渗透及对板性能的影响

反射荧光显微镜可观察水溶性酚醛树脂胶（ＰＦ）在杨木大片刨花中的渗透情况。通过显微观察及板内结合强度测试,结果表明,蒸汽冷凝水对水溶性ＰＦ树脂胶有稀释作用,改变胶的流动和渗透性能。采用喷蒸真空热压工艺时,须对水溶性ＰＦ胶进行改性,ＰＦ的分子量要大于传统工艺所要求的分子量,而且有必要采用适当的喷蒸保持时间     

伊维菌素对犬蠕形螨病的疗效观察

犬蠕形螨病是由蠕形螨寄生于犬皮脂腺或毛囊而引起的一种顽固性寄生虫性皮炎。本病的发生多是真菌细菌和蠕形螨的混合感染,一般治疗顺序是先杀细菌和真菌,然后再除螨,通过症状与实验诊断的方法诊出的病犬31只,用伊维菌素和辅助“二合一”,“抗真菌Ⅰ号”外洗综合治疗方法,痊愈28只,治疗效率很好。     

微量多拉菌素与伊维菌素对牦牛皮蝇幼虫驱除效力的研究

应用多拉菌素注射剂和伊维菌素浇泼剂微量给药,对自然感染皮蝇幼虫的犊牦牛进行驱虫效力研究。结果:给药后28~34d剖检和翌年3、5月份两次摸背检查远期防治效果,多拉菌素注射剂5μg/kg剂量组驱净率分别为85.0%和92.1%,驱虫率分别为93.6%、93.7%;10、20μg/kg剂量组均为100.0%。伊维菌素浇泼剂12.5μg/kg。剂量组驱净率分别为85.0%和91.2%,驱虫率分别为93.3%和93.2%;25、50μg/kg剂量组均为100.0%。对照组牦牛皮蝇1期幼虫感染率85.0%,平均感染强度29.7条;背部皮下瘤疱和皮肤虫孔的平均感染率84.1%,瘤疱和虫孔总数205个。试验证明供试两种药物使用微量驱除牦牛皮蝇1期幼虫高效安全经济,多拉菌素的最佳剂量为10μg/kg,伊维菌素的最佳剂量为25μg/kg。     

伊维菌素浇泼剂治疗猪疥螨病的效果观察

应用0.5%伊维菌素浇泼剂,按0.1~0.12mL/kg剂量治疗112头疥螨病患猪。结果表明,给药后14d治愈率达100%。     

伊维菌素浇泼剂对绵羊线虫的驱虫效力与安全性试验

应用0.5%伊维菌素浇泼剂按0.3,0.4,0.5mg/kg.b w剂量对绵羊沿背中线皮肤一次浇泼给药,并以伊维菌素注射剂0.2mg/kg.b w剂量做对照。结果:伊维菌素浇泼剂0.3mg/kg,0.4mg/kg.b w剂量对消化道线虫虫卵转阴率分别为85%和90%,减少率分别为89.1%和95.9%;对原圆科线虫幼虫转阴率分别为60%和75%,减少率分别为77.2%和86.7%;0.5mg/kg.b w剂量对消化道线虫虫卵转阴率和减少率均为100%,对原圆科线虫幼虫转阴率为85%,减少率为95.4%。解剖检查结果:伊维菌素浇泼剂三种剂量对绵羊消化道、呼吸道多属线虫均有效,总计驱虫率分别为90.8%,95.6%和99.7%,伊维菌素浇泼剂0.5mg/kg.b w剂量与伊维菌素注射剂0.2mg/kg.b w剂量驱虫效果基本一致;绵羊经皮给药可耐受1.0mg/kg.b w剂量。试验证明:伊维菌素浇泼剂经皮给药驱除绵羊线虫高效安全,临床推荐剂量以0.5mg/kg.b w为宜。     

Plasma pharmacokinetics and faecal excretion of ivermectin (Eqvalan paste) and doramectin (Dectomax, 1%) following oral administration in donkeys

Ivermectin (IVM- Eqvalan paste, 1.87%) and doramectin (DRM-Dectomax 1%) were each administered orally to donkeys at 200 microgkg(-1) bodyweight. Blood and faecal samples were collected at predetermined times over 30 days and plasma pharmacokinetics and faecal excretion determined. Maximum plasma concentrations (C(max)) of IVM (23.6 ngml(-1)) and DRM (33.9 ngml(-1)) were obtained at (t(max)) 19.2 and 24h, respectively. The area under the concentration curve (AUC) of DRM (228.9 ngdayml(-1)) was significantly larger than that of IVM (119.3 ngdayml(-1)) and mean residence time (MRT) was 6.5 days for IVM and 9.1days for DRM. The highest (dry weight) faecal concentrations (9.33 microgg(-1) - IVM, 12.12 microgg(-1) - DRM) were detected at 55.9 and 48.0 h, respectively and each compound was detected (0.05 microgg(-1)) in faeces between 11h and 9 days following oral administration in donkeys.     

伊维菌素微球在家兔体内的药动学

皮下注射伊维菌素 (IVM )微球悬液 (5 0mg/kg及 10 0mg/kg)和害获灭 (1%伊维菌素 ,0 5mg/kg) ,RP HPLC UV法定量 ,研究了IVM在家兔体内的药物动力学。害获灭皮下注射给药 ,药 时数据符合一级吸收一室开放模型 ,主要动力学参数为 :t1/2ka=7 2 4± 2 96h ;t1/2ke=36 38± 8 6 6h ;tmax=2 1 4 6± 4 82h ;Cmax=2 2 53± 2 32ng/ml;AUC =174 9± 318ng/1.h ,其动力学参数表现比较明显的个体差异 ,且与其它动物有明显差别。微球皮下注射一周后 ,血药浓度呈较稳定状态 ,到第 4 2天 (高剂量组 )和第 32天 (低剂量组 ) ,血浆中测不出H2 B1a(低于 2 5ng/ml)。以房室模型拟合 ,微球高低剂量组均符合有吸收二室开放模型 ,主要药动学参数均表现显著的个体差异。